The human c-myc proto-oncogene is transcribed from four alternative promoters (P0, P1, P2, and P3) giving rise to mRNAs having 5' leader sequences of various length. The c-myc P0 mRNA contains three open reading frames (ORFs), the last one encoding c-Myc1 and c-Myc2 proteins generated by alternative translation initiated at CUG and AUG codons. The middle ORF (MYCHEX1) and the 5' ORF (ORF1) code for proteins 188 and 114 amino acids in length, respectively. We and others previously identi®ed an internal ribosome entry site (IRES) in P0 and P2 c-myc mRNAs, promoting the cap-independent translation of c-Myc1 and c-Myc2. Here, we report the presence of a second IRES (named IRES1) promoting the cap-independent translation of MYCHEX1 in c-myc P0 mRNA. Using deletion analysis, we mapped an 80-nt region essential for IRES1 activity. c-myc P0 mRNA is thus the ®rst eukaryotic polycistronic mRNA described for which translation initiation of two dierent open reading frames (MY-CHEX1 and c-Myc1/c-Myc2) involves internal ribosome entry. Oncogene (2001) 20, 4270 ± 4280.
Introduction
The c-myc proto-oncogene encodes a transcription factor which regulates the expression of many genes involved in the control of cell proliferation, dierentiation and apoptosis (Obaya et al., 1999; Ryan and Birnie, 1996) . c-myc gene expression is controlled at many levels (Willis, 1999; Marcu et al., 1992) . In humans, it can be transcribed from four alternative promoters P0, P1, P2 and P3 (see Figure 1 ) the latter one being located in the ®rst intron of the gene (Bentley and Groudine, 1986a,b; Spencer et al., 1990) . P1 and P2 are the two most commonly used promoters, together accounting for approximately 90% of c-myc transcripts in normal cells. However, in Burkitt's lymphoma, P0 mRNA can represent 10% of the total c-myc mRNA pool versus 1 ± 5% in normal cells (Eick et al., 1990) . Moreover, a study of c-myc gene expression in 10 cell lines derived from patients with multiple myeloma showed that seven of these cell lines expressed exclusively c-myc P0 mRNA (Hoover et al., 1995) . P0, P1, and P2 mRNA translation can be initiated at least at two dierent initiation codons (CUG or AUG) leading to the synthesis of two proteins (c-Myc1 and c-Myc2) (Hann et al., 1988) having distinct roles in the control of cell proliferation (Blackwood et al., 1994; Hann et al., 1992 Hann et al., , 1994 . Recently, shorter Myc proteins (Myc-S) have been observed in dierent cell lines and were shown to be truncated forms of c-Myc2 initiated at downstream initiation codons (Spotts et al., 1997) . In contrast, P3 mRNA codes only for the c-Myc2 protein (Ray and Robert Lezenes, 1989) . P0 mRNA is a natural polycistronic mRNA containing three open reading frames (ORFs). Whereas the 3' ORF (ORF3) encodes c-Myc1 and c-Myc2 proteins, the two upper ORFs, ORF1 and MYCHEX1, code for proteins of 114 and 188 amino acids, respectively (Bentley and Groudine, 1986b; Gazin et al., 1986) . This feature is unique to the P0 transcript as P1, P2 and P3 mRNAs do not contain these upstream ORFs. As the transcription initiation sites of the P0, P1 and P2 c-myc mRNAs are located 1172, 524 and 363 nt upstream from the CUG Myc-1 initiation codon, the three transcripts dier in the length of their 5' leader sequences. Using the bicistronic vector assay, we and others previously demonstrated the presence of an internal ribosome entry site (IRES) in P0 and P2 mRNAs located between nucleotides 811 and 1077 of P0 transcript and which promotes cap-independent translation of cMyc1/c-Myc2 ORFs (see Figure 1 and Nanbru et al., 1997; Stoneley et al., 1998) . It was further reported that c-myc mRNA remains associated with polysomes under conditions in which cap-dependent translation is inhibited, indicating that c-myc IRES is functional in its natural context (Johannes and Sarnow, 1998) . Moreover, c-myc IRES activity is observed in apoptotic cells and during the G2/M transition of the cell cycle, two conditions in which cap-dependent translation is severely impaired (Pyronnet et al., 2000; Stoneley et al., 2000) . In vivo, the c-myc IRES is mainly active during embryogenesis, and is downregulated at later stages of development (CreÂ ancier et al., 2001) .
IRESs, originally discovered in messenger RNAs from picornaviruses (Jackson, 1988; Pelletier and Sonenberg, 1988) , are also found in a few cellular mRNAs containing long 5' UTRs (e.g. IGF-II, VEGF, PDGF, Xiap, DAP5, PITSLRE mRNAs) (Akiri et al., 1998; Bernstein et al., 1997; Cornelis et al., 2000; Henis-Korenblit et al., 2000; Holcik et al., 1999; Huez et al., 1998; Sella et al., 1999; Teerink et al., 1995) . The IRESs identi®ed so far, dier in their primary sequences but display some similarities in their secondary structures that appear to be crucial for IRES activity (Le and Maizel, 1997) . However, IRESs can also correspond to short motifs, as a 9-nt sequence present in Gtx mRNA 5'UTR promotes internal translation initiation .
In picornaviruses, the internal entry process has been shown to require cellular trans-acting factors such as PTB, La, PCBP2 and unr (Blyn et al., 1996 (Blyn et al., , 1997 Hellen et al., 1993; Hunt et al., 1999) . In contrast, little is known concerning the trans-acting factors involved in the activity of cellular IRESs (Huez et al., 1998; Sella et al., 1999; Yang and Sarnow, 1997) , except the involvement of the La autoantigen in the IRESmediated translation of Xiap mRNA (Holcik and Korneluk, 2000) .
Here, we report the identi®cation and the characterization of a second IRES located in the 5' leader of c- myc P0 mRNA. We also demonstrate that this IRES promotes the cap-independent translation of MY-CHEX1 ORF.
Results
Identification of a second IRES in the c-myc P0 mRNA 5' UTR c-Myc1 and c-Myc2 proteins can be decoded from P0, P1 and P2 c-myc mRNAs by a cap-independent mechanism involving an IRES located upstream of cmyc CUG initiation codon (Nanbru et al., 1997; Stoneley et al., 1998) . As P0 mRNA 5' leader contains an 811 nt-long region upstream of the previously identi®ed IRES (here named IRES2; Figure 1) , we investigated the existence of an additional IRES within this region. Indeed, the presence of two independent IRESs has been recently discovered in the human VEGF mRNA 5' untranslated region (UTR) (Huez et al., 1998) . Therefore, the bicistronic vector assay was used to evaluate the existence of such elements within the upstream region of the P0 5' UTR. This strategy is based on the principle that the second ORF of a bicistronic mRNA is eciently translated only when it is preceded by an IRES. Moreover, the introduction of a stable hairpin structure upstream of the ®rst ORF should inhibit its cap-dependent translation without aecting the IRES-mediated translation of the downstream ORF. Therefore, we generated a pair of bicistronic DNA constructs pBI MyCAT P0*P1, pBI MyCAT NRS(415) in which the ®rst 644 nt of P0 mRNA leader or a control sequence were respectively inserted in the intercistronic region between the CAT and the Myc-CAT ORFs (Figure 2a ). Another pair of bicistronic vectors was derived from the ®rst by the introduction of a stable hairpin structure upstream of the ®rst ORF (pHP MyCAT P0*P1, pHP MyCAT NRS(415)). In both constructs containing the P0*P1 region, the P1 promoter TATA box was mutated to abolish transcription initiation at the P1 site. HeLa cells were transiently transfected with these bicistronic constructs, with or without a hairpin, and the translation products were analysed by Western blot using anti-CAT antibody. As shown in Figure 2b , the expression of Myc-CAT protein could be observed upon insertion of the P0*P1 leader in the intercistronic region whereas no expression of this protein was detected with the pBI/HP MyCAT NRS(415). Furthermore, the presence of a 5'-hairpin structure in the bicistronic constructs strongly inhibited CAT expression without aecting Myc-CAT synthesis, thereby con®rming that expression of the second cistron was not due to a reinitiation event (compare lanes 1, 2 and to 7, 8). These results indicate that the P0 mRNA 5' leader region contains an IRES (that we named IRES1) in addition to that previously described (here named IRES2).
A number of additional bicistronic constructs containing 5' shortened intercistronic sequence of P0*P1 UTR, with or without a 5' hairpin, were generated in order to localize more precisely the IRES1 boundaries in c-myc P0 mRNA (MyCATP0*P1/D350, MyCATP0*P1/D545, see Figure 2a ). IRES1 is localized between nt 545 and 644 of the P0 transcript as expression of MyCAT cistron is maintained upon deletion up to nt 545 of the P0 5' leader ( Figure 2b ) but disappears upon deletion beyond nt 644 (see BI, HP MyCAT NRS(415) (Figure 2b ) and BI, HP MyCATD2 in (Nanbru et al., 1997) ).
The integrity of the bicistronic mRNAs was veri®ed by Northern blot analysis, which showed that mRNAs encoded by the dierent transfected constructs migrated at the expected size and were expressed in equal amounts (Figure 3 ).
Binding of PTB to P0 mRNA 5' UTR upstream from IRES1
In order to identify factors interacting with c-myc 5'UTR, UV cross-linking experiments were performed with RNA probes corresponding to the dierent c-myc leaders (myc P0, myc P0*, myc P1 and myc P2) in the presence of HeLa cytoplasmic extract ( Figure 4a ). As controls, we used 32 P-labeled RNA probes corresponding to EMCV IRES or to myc D2 in which IRES2 has been removed from the P2 5' c-myc leader (Nanbru et al., 1997) . As shown in Figure 4b (left panel), P0 and P0* RNA probes bound a protein doublet of 60 kDa co-migrating with the EMCV cross-linked PTB, known to be involved in the IRES activity of several picornavirus. The identi®cation of the 60 kD-doublet bound to the myc P0, P0* probes as PTB was con®rmed by immunoprecipitation of the myc P0 cross-linked products with anti-PTB antibodies ( Figure  4b , right panel). Unexpectedly, no protein was found to bind speci®cally to myc P1 or P2 leaders which contain IRES2. The absence of PTB-binding on myc P1 and P2 RNA probes indicated that this protein interacted with the upstream part of the P0 leader (between nt 1 and 644), containing IRES1. Therefore, UV cross-linking experiments were performed using RNA probes in which the 115, 350 or 545 ®rst nucleotides of myc P0*P1 leader were deleted ( Figure  4a ). RNA probes corresponding to myc P0*P1, myc P0*P1/D115 were able to bind the PTB with the same eciency as myc P0* (Figure 4c , compare lanes 2, 3 to 1). In contrast, PTB-binding was eliminated by further deletion of P0*P1 leader ( Figure 4c , see lanes 4, 5), indicating that PTB binds to P0 5'UTR between nts 115 and 350. It should be noted that this region of P0 leader is not involved in IRES1 activity, which implies discordance between PTB binding and IRES1 activity.
IRES1 promotes MYCHEX1 translation from P0 mRNA
The c-myc P0 mRNA contains several open reading frames including ORF1, MYCHEX1 and c-Myc1, cMyc2 ( Figure 5a ). As mentioned above, in addition to c-Myc1/c-Myc2 ORFs, MYCHEX1 ORF has also been shown to be expressed in HeLa cells (Gazin et Two independent IRESs in the human c-myc P0 mRNA C Nanbru et al al., 1986). Whereas IRES2 is located upstream of cMyc1/c-Myc2 ORFs and confers cap-independent translation of c-Myc1 and c-Myc2 (Nanbru et al., 1997; Stoneley et al., 1998) , the IRES1 identi®ed in P0 mRNA is located upstream of MYCHEX1 ORF ( Figure 5a ).
In order to identify ORF1 and MYCHEX1 translation products from c-myc P0 mRNA, we generated four DNA constructs in which these ORFs were tagged by in-frame insertion of the sequence encoding the hemagglutinin (HA) epitope, thereby allowing immunodetection of the tagged proteins. In the pTag 7 Figure 2 Identi®cation and mapping of a second IRES in the c-myc P0 mRNA 5'UTR. (a) Schematic representation of the bicistronic DNA constructs used for transfection experiments. The dierent c-myc leaders were fused to the CAT coding sequence (143 nt downstream from ATG codon), with the two initiation codons CTG and ATG of c-myc in frame with the CAT ORF. This fusion gives rise to a chimeric Myc-CAT protein of 32 kDa (ATG/Myc-CAT2) and 34 kDa (CTG/Myc-CAT1)(see Materials and methods). The chimeric Myc-CAT constructs were subcloned downstream from the CAT coding sequence under the control of the CMV promoter. The resulting plasmids (pBI MyCAT) encode bicistronic mRNAs having two tandem CAT ORFs with dierent sizes. The pHP MyCAT DNAs are derived from the pBI DNAs with the addition of a 5'-hairpin (DG=740 kcal/mol). The sizes of the dierent intercistronic regions inserted between CAT and Myc-CAT are indicated, nucleotide numbering starting at the ®rst nucleotide of P0 transcript. P0*P1 includes the ®rst 644-nt of P0* leader fused with the 95-nt long sequence localized upstream of the c-myc CUG initiation codon (* specifying mutations of the P1 and P2 TATA boxes). P0*P1/D350 and D545 correspond to the P0*P1 region lacking the ®rst 350 and 545 nt, respectively. NRS(415) is a control sequence corresponding to 415-nt of TNF 3' UTR region fused with the 95-nt long sequence localized upstream from c-myc CUG initiation codon. (b) HeLa cells were transfected with the bicistronic vectors described in (a) and the expression of the dierent constructs was analysed by Western immunoblotting using an anti-CAT antibody allowing the simultaneous detection of both ORF products (CAT and Myc-CAT). The same amount of protein extract was loaded on the gel. The name of the transfected constructs, as well as the presence (+) or the absence (7) of a hairpin are indicated. CAT, Myc-CAT1 and Myc-CAT2 products are indicated. The ®gure is representative of at least three independent experiments Oncogene Two independent IRESs in the human c-myc P0 mRNA C Nanbru et al construct, the 5' P0 sequence was inserted downstream from the T7 promoter (Figure 5b ). The pTag ORF1 and/or MYCHEX1 were derived from the pTag 7 construct with the tag sequence inserted in the amino and/or carboxy terminal side of ORF1 and MY-CHEX1 (Figure 5b ). An equal amount of capped mRNA corresponding to each construct was translated in WGE. As shown in Figure 5c (left panel), ORF1 and MYCHEX1 proteins migrated according to their expected molecular mass (ORF1: 12.5 kDa, MY-CHEX1: 21 kDa) and a migration shift was observed upon tagging of each ORF (Figure 5c , left panel). It should be noted that an additional protein (named here ORFx) was detected upon electrophoresis of pTag ORF1 or pTag ORF1/MYCHEX1 mRNA translation products. However, it could not be distinguished from untagged ORF1 derived from pTag 7 and pTag MYCHEX1 mRNA translation (compare lanes 2 and 4 to 3 and 5). Based on its apparent molecular mass (11 kDa), ORFx product might correspond to an alternative initiation within ORF1 (Figure 5a ).
To con®rm that the shifted bands corresponded to ORF1 and MYCHEX1 tagged proteins (left panel), tagged products were identi®ed by immunoprecipitation with anti-HA antibody. As shown in Figure 5c (right panel), immunoprecipitated ORF1 and MY-CHEX1 proteins were obtained only with translation reactions programmed with mRNAs encoding tagged ORF1 and/or MYCHEX1 proteins (compare lanes 7, 8, 9 to 6). Altogether, these experiments demonstrated that ORF1 and MYCHEX1 are translated from P0 mRNA in WGE.
In order to determine whether IRES1 promoted translation of MYCHEX1, we compared the translation of Tag ORF1/MYCHEX1 mRNA with a control mRNA encoding the same ORFs, but in which the IRES1 located in the intercistronic region was replaced by a control sequence of similar length (NRS(188)) (Figure 6a ). Tag MYCHEX1 synthesis was only detected when the system was programmed with the Tag ORF1/MYCHEX1 construct whereas Tag ORF1 and ORFx proteins were equally expressed using both mRNAs (Figure 6b, left panel) . Moreover, translation of capped and uncapped Tag ORF1/MYCHEX1 mRNAs generated equal amounts of Tag MYCHEX1 protein whereas Tag ORF1 and ORFx translation was signi®cantly weaker with uncapped mRNA, indicating that MYCHEX1 ORF translation is mediated by IRES1. Northern blot analysis con®rmed the integrity and the equal amount of mRNA introduced in the translation reactions (Figure 6b, right panel) .
The IRES1-mediated translation of MYCHEX1 ORF was further con®rmed by the observation that the addition of cap analog in the translation reaction did not aect MYCHEX1 ORF translation whereas ORF1 and ORFx protein synthesis was signi®cantly decreased (Figure 6c ).
Discussion
We previously identi®ed an IRES mediating capindependent translation of c-Myc 1/c-Myc 2 ORF in the human c-myc P0 and P2 mRNAs (named here IRES2) (Nanbru et al., 1997) . Here, we show that cmyc P0 mRNA, which has the longest 5' leader, contains an additional IRES (named here IRES1). IRES1 promotes the cap-independent translation of MYCHEX1 ORF in the WGE. Similar observations were obtained in the rabbit reticulocyte lysate (data not shown). c-myc P0 mRNA is thus the ®rst eukaryotic polycistronic mRNA described in which two dierent open reading frames (MYCHEX1 and c-Myc1/c-Myc2) are translated by internal ribosome entry. Moreover, the presence of ORF1 upstream from the ORF encoding MYCHEX1, as well as the 230-nt distance separating both ORFs, imply that the MYCHEX1 ORF is exclusively translated by this internal mechanism.
Deletion analysis of the c-myc P0 mRNA 5' leader placed IRES1 at a position delimited by nt 545 and 644 of the P0 mRNA (Figure 2 ). Considering that in its natural context, IRES1 promotes MYCHEX1 ORF translation initiation, it is located within the 80-nt long sequence upstream of MYCHEX1 initiation codon (see Figure 5a ).
UV-crosslinking experiments revealed PTB binding to P0 5' UTR (Figure 4) . However, as for VEGF IRES, PTB binding involves a sequence outside the IRES region (Huez et al., 1998) , indicating that PTB binding does not necessarily imply its requirement for IRES activity (Kaminski and Jackson, 1998) . Besides PTB, no other protein was found to bind speci®cally In vitro translation of MYCHEX1 ORF has been previously reported by others (Gazin et al., 1986; Bentley and Groudine, 1986b) . However, MYCHEX1 migrated as a 32 kD-protein on SDS page: a fact that is in disagreement with the theoretical mass and the molecular mass observed by us (Figure 5b ) and by others (Bentley and Groudine, 1986b) . At this point, we have no explanation for this discrepancy. So far, the function of MYCHEX1 protein has not been elucidated. The capacity of P0 mRNA to encode 32 P-labeled RNA probe corresponding to c-myc P0 leader was cross-linked with proteins presented in a HeLa S10 extract, and the complex was immunoprecipitated with anti-PTB antibody. The samples were analysed before (7) and after (+) immunoprecipitation (IP) (right panel, lanes 7 and 8). PTB is indicated by an arrow. (c) UV cross-linking experiments were performed as in b) with a P0*P1 RNA probe or deleted versions of the P0*P1 region (see a) and with EMCV IRES as control. PTB is indicated by an arrow Oncogene Two independent IRESs in the human c-myc P0 mRNA C Nanbru et al MYCHEX1 is a unique feature of human c-myc mRNA. Indeed, despite 70% homology between human and mouse c-myc exon 1, the murine sequence is non-coding (Corcoran et al., 1985) . It should be mentioned however, that polypeptides closely related to human MYCHEX1 can be found in mouse cells, indicating the existence of a cognate gene elsewhere in the mouse genome (Dedieu et al., 1988) .
P0 mRNA transcription has been detected in several human cell types (HeLa, HL-60, K562, Daudi, 293, COLO-320 cells, _) (Gazin et al., 1986) . Interestingly, P0 mRNA can represent a signi®cantly greater proportion of the total c-myc mRNA pool in Burkitt's lymphoma (10% versus 1 ± 5%) (Eick et al., 1990) . Furthermore, it is the only c-myc mRNA transcribed in 7 out of 10 cell lines derived from patients with multiple myeloma (Hoover et al., 1995) . Although it remains to be determined whether MYCHEX1 protein is produced in these cells, we have provided evidence for the existence of a cap-independent mechanism allowing MYCHEX1 ORF translation. The demonstration of MYCHEX1 synthesis by a cap-independent mechanism raises interest in the physiological role of cmyc P0 mRNA and its MYCHEX1 ORF. MYCHEX1 overexpression experiments should contribute to the understanding of the role of this protein.
Alternatively, MYCHEX1 protein synthesis could modulate c-Myc1/c-Myc2 ORF translation from P0 mRNA. In this respect, it is worth mentioning that MYCHEX1 ORF overlaps with IRES2, which directs c-Myc1/c-Myc2 protein synthesis (Figure 5a ). MY-CHEX1 ORF translation could thus lead to partial IRES2 unfolding and inactivation, thereby inhibiting cap-independent c-Myc1/c-Myc2 ORF translation. Comparative analysis of the translation of MYCHEX1 and c-Myc1/c-Myc2 ORFs from P0 mRNA containing or lacking IRES1 should reveal whether c-Myc1/cMyc2 synthesis is modulated by the translation of the upstream MYCHEX1 ORF.
Materials and methods

Plasmid constructions
The pBI /HP MyCAT P0*P1, MyCAT D350, D545 and MyCAT NRS(415) were derived from the DNA previously described pHP-FC1 and pBI-FC1 (Vagner et al., 1995a) . The pBI/HP are bicistronic constructs containing a variable intercistronic region (P0*P1, D350, D545 and NRS(415)) between the two ORFs (CAT and Myc-CAT) under the control of T7 and cytomegalovirus (CMV) promoters ( Figure  2a) . The chimeric Myc-CAT protein is encoded by a fusion of 143-nt downstream from c-Myc AUG codon to the CAT coding sequence. The series of bicistronic vectors pHP MyCAT derived from the pBI series but contain a 5' hairpin (740 kcal/mol) upstream the CAT ORF. In all these constructs, the 3' intron region was deleted by a BglII cleavage.
The dierent constructs were obtained by PCR ampli®ca-tion and the PCR products were introduced by the same strategy in a monocistronic plasmid upstream the CAT gene between XbaI ± HindIII sites (derived from pFC1, previously named pSCT in Prats et al., 1992) . The bicistronic constructs were derived from the monocistronic constructs by insertion of XbaI ± SstI fragment (variable 5' region fused to Myc-CAT) in the pBI or pHP vectors downstream the ®rst ORF (CAT). The pSCT MyCAT P0*P1 contains the 644 upstream nucleotides (counting from P0 mRNA 5' end) fused to the fragment from nt 1077 ± 1173 (Figure 2 ). It was obtained by a ®rst PCR ampli®cation of the plasmid pSCT MyCATD2 (Nanbru et al., 1997) using oligonucleotides O438 (5'-CATATGCGAGGGTCTGGACGGCTCGACGCGGGGA-GGCTATTC-3') and O413 (5'-ACGTGATCCCAAGCTT-GATATCCTCGCTGGGCGCCGG-3') as 5' and 3' primers, respectively (PCRA) and a second PCR ampli®cation was performed using the plasmid pSCT MyCATP0* (Nanbru et al., 1997) with oligonucleotides O409 (5'-ACGTGATC-CCTCTAGAAACAAATGCAATGGGAGTTTATTCAT-3') and O439 (5'-AGCCGTCCAGACCCTCGCATATGAAA-GGG-3') (PCRB). PCRA and PCRB fragments were puri®ed and a third PCR (PCRC) ampli®cation was performed by combining the two PCR products obtained (PCRA and PCRB) with external oligonucleotides (O409 and O413). The PCRC fragment was digested at the XbaI and HindIII sites (underlined sequence) and inserted upstream of the CAT gene into the monocistronic plasmid cleaved by the same enzymes. The MyCAT P0*P1/D350, with a 5' deleted sequence of 350-nt compared to the MyCAT P0*P1, was constructed by PCR ampli®cation of plasmid pSCT MyCAT P0*P1 using oligonucleotides O544 (5'-ACGTGATCCCTCTAGACAAA-CAGTACTGCTACGGAGGAGC-3') and O413. The PCR fragment was digested at the XbaI and HindIII sites (underlined sequence) and introduced upstream of the CAT gene into the monocistronic plasmid cleaved by the same enzymes. The pSCT MyCAT P0*P1/D545 with a 5' deleted sequence of 545-nt compared to the MyCAT P0*P1 was obtained using the same strategy with primers O545 (5'-ACGTGATCCCTCTAGACCCGGGTTCCCAAAGCAGA-GGGCG-3') and O413. The pSCT MyCAT NRS (415) (Non Related Sequence) was obtained by a ®rst PCR ampli®cation of the plasmid pSCT MyCATD2 using oligonucleotides O441 (5'-CATCTCTTTGCGGAGGCCTC-GACGCGGGGAGGCTATTC-3') and O413 (PCRD). A second PCR ampli®cation was performed with the plasmid SP64 3'TNFAU 7 (Gueydan et al., 1996) using oligonucleotides O440 (5'-ACGTGATCCCTCTAGAAGGCCTTCCTA-CCTTCAGACCTTT-3') and O442 (5'-AGGCCTCCG-CAAAGAGATGGATG-3') (PCRE). PCRD and PCRE fragments were puri®ed and a third PCR (PCRF) ampli®ca-tion was performed by combining the two PCR products obtained (PCRD and PCRE) with external oligonucleotides (O440 and O413). The PCRF fragment was digested at the XbaI and HindIII sites (underlined sequence) and introduced upstream the CAT gene into the monocistronic plasmid cleaved by the same enzymes.
The pTag ORF1 construct contains an insertion at nt-58 (nt-1 corresponds to the 5' extremity of P0 mRNA) of a tag sequence encoding 9 aa (hemagglutinin HA epitope) in frame with ORF1 in the amino-terminal part of the protein. This construct was obtained by a ®rst PCR ampli®cation of the plasmid pSCT MyCAT P0* using oligonucleotides O568 (5'-ACGTGATCCCGGATCCAACAAATGCAATGGGAGTT-TATTCAT-3') and O569 (5'-agcgtaatctggaacatcgtatgggta-ACGCATTGCCACGTATACTTGGA-3') (small characters: HA tag sequence, PCRG). A second PCR ampli®cation was performed with the plasmid pSCT MyCATP0* using oligonucleotides O570 (5'-tacccatacgatgttccagattacgctTGC-TGGGTTATTTTAATCATTCT-3') and O571 (5'-GGG-GCCCGGCGGTGGCGGCCGCGAGCAGCACAGCTC-3') (PCRH). PCRG and PCRH fragments were puri®ed and a third PCR (PCRI) ampli®cation was performed combining the two PCR products obtained (PCRG and PCRH) with external oligonucleotides (O568 and O571). The PCRI fragment was digested at the BamHI and NotI sites (underlined sequence) and introduced into the pSCT MyCAT P0* digested with the same enzymes.
The pTag MYCHEX1 construct which contains an inserted sequence encoding the HA tag at nt-1188 (nt-1 corresponds to the 5' extremity of P0 mRNA) in frame with MYCHEX1 in the carboxy-terminal part of the protein was Two independent IRESs in the human c-myc P0 mRNA C Nanbru et al obtained by the same strategy as the pTag ORF1. A ®rst PCR ampli®cation was performed with the plasmid pSCT MyCAT P0* using oligonucleotides O572 (5'-CCC-CCGAGCTGTGCTGCTCGCGGCCGCCACCGCCGG-3') and O573 (5'-CTATTAagcgtaatctggaacatcgtatgggtaCCCGA-AAAAAATCCAGCGTCTAA-3') (PCRJ) and a second PCR ampli®cation was performed with the plasmid pSCT MyCAT P0* using oligonucleotides O574 (5'-tacccatacgatgt-tccagattacgctTAATAGTGGAAAACCAGCAACCTCCC-3') and O413 (PCRK). PCRJ and PCRK fragments were puri®ed and a third PCR (PCRL) ampli®cation was performed by combining the two PCR products obtained (PCRJ and PCRK) with external oligonucleotides (O572 and O413). The PCRL fragment was digested at the HindIII and NotI sites (underlined sequence) and introduced into the pSCT MyCAT P0* cleaved by the same enzymes. The pTag ORF1/MYCHEX1 resulted from the ligation of the pTag ORF1 digested by HindIII ± NotI and the HindIII ± NotI fragment of pTag MYCHEX1 construct including Tag MYCHEX1. In pNRS(188) (Non Related Sequence), IRES1 was removed and replaced by a segment corresponding to 188 nt of the mouse TNF 3'UTR (derived from the SP64 3'TNF AU
7
). This deletion/replacement was obtained by ®ve independent PCR ampli®cations. The PCRM fragment was obtained after ampli®cation of the plasmid pTag ORF1/ MYCHEX1 using oligonucleotides O568 and O618 (5'-TTATTAAGACAATTGGGTTAGTTTTCTTTTGCTCCC-TCTCA-3'). PCRN fragment was obtained after ampli®ca-tion of the plasmid pTag ORF1/MYCHEX1 using oligonucleotides 0620 (5'-CATCTCTTTGCGGAGGCCTCCGGCC-CTTTCATATGCGAGGG-3') and O413. PCRO fragment was obtained after ampli®cation of the plasmid SP643'TNFAU 7 using oligonucleotides O619 (5'-CTAACC-CAATTGTCTTAATAACGC-3') and O442. PCRP fragment was obtained by ampli®cation of the two PCRM and PCRO puri®ed products with external oligonucleotides O568 and O442. PCRQ fragment was obtained by ampli®cation of the two PCRP and PCRN puri®ed products with external oligonucleotides O568 and O413. The PCRQ fragment was digested by BamHI and HindIII and introduced into the pSCT MyCAT P0* digested by the same enzymes. All the constructs were subsequently sequenced.
In vitro transcription and translation
The plasmids were linearized downstream from the 3' end of the MYCHEX1 coding sequence at the HindIII site. Capped and uncapped mRNAs were generated with the T7 mMessage mMachine kit (in the presence of 0.5 mM m 7 GpppG for capped mRNAs) or the T7 Megascript kit (uncapped mRNAs) from Ambion according the manufacturer's instructions. In vitro translation in wheat germ extract (WGE) (Promega) was performed as previously described (Prats et al., 1992) in the presence of L-[ 35 S]cysteine (ICN Biomedicals). The translation products (1/20 of translation) were separated by electrophoresis in a Tris-Tricine polyacrylamide gel (Ausubel et al., 1995) , ®xed in methanol 30%-acetic acid 10%, followed by¯uorography in 1 M sodium salicylate and by autoradiography.
DNA transfection and Western immunoblotting
HeLa cells were grown in DMEM 5% Fetal Calf Serum (Life Technologies) and were transfected using the Fugene-6 transfection reagent (Roche) according to the manufacturer's instructions (250 ng of DNA). Twenty-four hours after transfection, cell lysate was prepared and used for Western immunoblotting as previously described (Vagner et al., 1995a) .
RNA extraction
Total cellular RNA was prepared by the Trizol method (Life Technologies), according to the manufacturer's instructions. Extraction of RNA from the WGE was performed by diluting a 1/4 of the translation reaction (5 ml) in 200 ml of a buer solution (1% SDS, 1 mM EDTA, 300 mM sodium acetate, 2 mM Tris-HCl (pH 7.4)), RNA was subsequently extracted twice with phenol/chloroform and precipitated with ethanol (10 mg of tRNA was added as carrier) and the pellet was dissolved in denaturing buer (89% formamide, 10% glyoxal, 0.025% Xylene Cyanol, 0.025% Bromophenol blue, 18 mM EDTA, 0.025% SDS).
Northern blotting
Five mg of total RNA samples were loaded on a 1.2% agarose gel and Northern blot was performed as described (Kruys et al., 1993) . CAT or MYCHEX1 antisense RNA probes were generated with the T7 Maxiscript kit (Ambion) according to the manufacturer's instructions, using a linearized DNA template in the presence of 80 mCi [a- 
Immunoprecipitation of HA-tagged proteins
The HA-tagged proteins generated in WGE were immunoprecipitated with protein-A Sepharose beads (Pharmacia) as follows. Seventy ml of the translation reactions were diluted in 400 ml of lysis buer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, protease inhibitor cocktail (Roche), 1 tablet/10 ml) containing 0.4 ml of HA antibody (Babco PRB-101C). The proteins were precipitated with protein A-Sepharose beads (Pharmacia) and analysed by Tris-Tricine polyacrylamide gel electrophoresis.
UV-crosslinking assay
Monocistronic DNA constructs were linearized by HindIII and transcribed with T7 RNA polymerase in the presence of 80 mCi of [ 32 P]UTP and 10 mM UTP. Cytoplasmic extracts from HeLa cells and UV-crosslinking were performed as described (Huez et al., 1998) except that 25 ng of calf liver tRNA (Roche) was added in the binding reaction. Half of the reaction was heated for 5 min at 958C in SDS ± PAGE buer, and loaded on a 15% polyacrylamide gel. When indicated, the cross-linked products were immunoprecipitated with anti-PTB antiboby as described in (Huez et al., 1998; Vagner et al., 1995b) .
